Cardiovascular
disease accounts for 17 million deaths
worldwide each year, making it the
greatest risk to life for most adults.
Our world leading position in CV is
based on over 40 years' experience
and a powerful range of products including
Atacand for hypertension, Seloken
ZOK, a leader in its class of beta
blockers, and the latest addition
to our CV range, Crestor, for treating
high cholesterol levels.
AstraZeneca has a strong CV franchise
in India and a portfolio of products
which aims to increase the lifespan
and improve the quality of life of
patients by reducing the risk, prevalence
and impact of CV disease. There is
a growing incidence of heart disease
in India due to the pressures of modern
living. Hypertension is a silent killer
disease of the times. The incidence
in India is 2.5 times more than in
developed countries. The prevalence
in the urban population is about 15%
(5.3 Mn. patients). It is estimated
that by the year 2020, every 5th Diabetic
will be an Indian and in terms of
chronic illness, the major incidence
of disease will be in the cardiovascular
area.
Key
Products
More information
about our products is available by
clicking on the product names below.
.gif) Betaloc
(metoprolol tartrate)
Betaloc
H (metoprolol tartrate & hydrochlorothiazide)
Imdur
(Isosorbide-5-mononitrate)
Plendil
(Felodipine)
Ramace
(Ramipril)
Ramace
H (Ramipril & Hydrochlorothiazid)
Seloken
XL ( Metoprolol CR/XL)
Zestril
(Lisinopril dihydrate)
|